Moderna Has a Promising New Flu mRNA Vaccine. Trump’s FDA Wants Nothing to Do With It

Moderna has developed a promising new mRNA-based flu vaccine, but the Food and Drug Administration (FDA) has reportedly rejected the company's application. According to the article, a senior FDA official, Vinay Prasad, overrode his staff's recommendation to approve the vaccine. The decision is seen as a blow to Moderna's efforts to diversify its product portfolio beyond COVID-19 vaccines. The article suggests that the rejection may be politically motivated, as Prasad is a Trump-era appointee, and the former administration was known for its skepticism towards mRNA technology. However, the article does not provide definitive evidence to support this claim. The article highlights the ongoing tensions between the FDA and pharmaceutical companies, as the agency grapples with balancing safety concerns and the need for new medical treatments. It remains to be seen whether Moderna will resubmit its application or pursue alternative regulatory pathways for the new flu vaccine.